Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 14, 2018, the Board of Directors approved "inducement" grants to nine new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Pasadena. CA | Posted on September 25th, 2018

The option grants entitle the employees, in aggregate, to purchase up to 104,000 shares of common stock. The strike price of options is set at an exercise price per share of $18.91, the last reported closing price of the Company's common stock on September 14, 2018, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of five new employees, anticipated to be within 30 days of the date of the approval. The grants are outside of the Company's stockholder-approved equity incentive plans. The options vest and become exercisable over a period of four years.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Synopsys and GLOBALFOUNDRIES Collaborate to Develop Industry’s First Automotive Grade 1 IP for 22FDX Process: Synopsys’ Portfolio of DesignWare Foundation, Analog, and Interface IP Accelerate ISO 26262 Qualification for ADAS, Powertrain, 5G, and Radar Automotive SoCs February 22nd, 2019

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Possible Futures

Synopsys and GLOBALFOUNDRIES Collaborate to Develop Industry’s First Automotive Grade 1 IP for 22FDX Process: Synopsys’ Portfolio of DesignWare Foundation, Analog, and Interface IP Accelerate ISO 26262 Qualification for ADAS, Powertrain, 5G, and Radar Automotive SoCs February 22nd, 2019

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Investments/IPO's/Splits

A Nanobiotechnology Startup from a small town in India attracts the Global Investors January 27th, 2019

Nanobiotix Plans to Conduct Registered Public Offering in the United States January 17th, 2019

Nanometrics to Participate in the 21st Annual Needham Growth Conference January 7th, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) December 18th, 2018

Nanomedicine

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Announcements

Synopsys and GLOBALFOUNDRIES Collaborate to Develop Industry’s First Automotive Grade 1 IP for 22FDX Process: Synopsys’ Portfolio of DesignWare Foundation, Analog, and Interface IP Accelerate ISO 26262 Qualification for ADAS, Powertrain, 5G, and Radar Automotive SoCs February 22nd, 2019

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Nanobiotechnology

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Sensitive sensor detects Down syndrome DNA February 14th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project